CRIS
$0.77+0.01 (+1.89%)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Recent News
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ...
Curis Inc (CRIS) reports a significant quarterly profit, strategic advancements in clinical trials, and a solid financial outlook despite annual losses.
Curis, Inc. Q4 2025 Earnings Call Summary
Moby summary of Curis, Inc.'s Q4 2025 earnings call
Curis (CRIS) Q4 2025 Earnings Call Transcript
As you recall, last quarter we engaged with a number of KOLs who were excited and highly supportive about expanding our emavusertib studies into additional NHL subtypes. Over the last decade, BTK inhibitors have become the standard of care in CLL and NHL because of their ability to help patients achieve objective responses.
Curis: Q4 Earnings Snapshot
LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Thursday reported net income of $19.4 million in its fourth quarter.
How The Curis (CRIS) Narrative Is Evolving As Assumptions Shift But The Target Stays
Curis is back in focus as analysts reaffirm a $14.00 per share fair value, holding the line on their headline price target even as they revisit the assumptions underneath it. Rather than moving that $14.00 figure, recent commentary is centering on whether the current target still makes sense given the latest thinking on execution risks, profitability, and valuation support. As you read on, you will see how this updated narrative is evolving and what it could mean for tracking Curis from...